Please login to the form below

Not currently logged in
Email:
Password:

Germany launches USD 1.1bn initiative to boost pharmaceutical research

Germany launches a USD 1.1bn initiative to boost pharmaceutical R&D in the region.

According to local media reports, Germany has launched an initiative to boost pharmaceutical R&D in the region.

The new 'Pharma-Initiative' has a budget of EUR 800m (USD 1.1bn) and will run until 2011.

Germany's declining pharmaceutical sector has been highlighted by studies which have demonstrated that only a small percentage of approved pharmaceuticals are produced by German pharmaceutical firms. Innovation is largely driven by the US, the UK and Switzerland.

According to the Ministry for Research and Education, the new initiative will augment the innovation capacity of the pharmaceutical sector and promote pharmaceutical production concepts which unite the whole value chain, from the research laboratory right through to the production stage.

The mainstay EUR 100m-fund is called ìBioPharma: the strategy competition for the medicine of the futureî. Business-led consortia have been invited to suggest strategic concepts, which will see biopharmaceutical innovations through from research to application.

The German government is focusing on consortia which want to establish enduring links between the different stages of the process, most of which will be performed in Germany.

Germany is the third largest pharmaceutical market in the world and is the largest in Europe. Although the domestic consumption of pharmaceuticals is being constrained by government policy, the export market continues to expand. Germany also has the largest generic market in the EU. According to a PMLive Focus on Germany report, spending on drugs was EUR 23.4bn, while per capita health spending was EUR 2,900.

30th July 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist
...
Erik
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...

Infographics